NCT00492102View on ClinicalTrials.gov

Montelukast in Very Low Birthweight Infants

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Bronchopulmonary Dysplasia
Interventions
DRUG

Montelukast

One oral dose of Montelukast 0.15mg (infants weighing 500-1000gm) or 0.2mg (infants weighing \>1000gm). Two blood samples will be obtained from each infant within 24 hours of the drug administration and plasma Montelukast levels will be determined.

Trial Locations (1)

45220-2489

Good Samaritan Hospital, Cincinnati

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT00492102 - Montelukast in Very Low Birthweight Infants | Biotech Hunter | Biotech Hunter